Folic acid-targeted pluronic F127 micelles improve oxidative stress and inhibit fibrosis for increasing AKI efficacy

Eur J Pharmacol. 2022 Sep 5:930:175131. doi: 10.1016/j.ejphar.2022.175131. Epub 2022 Jul 21.

Abstract

The oxidative stress and activation of the fibrosis pathway are essential pathological mechanisms of acute kidney injury (AKI). In this article, we designed a drug delivery system that could effectively improve oxidative stress and relieve fibrosis by the combination of precise targeting, solubilization, and reducing the toxicity of nano-transport system to strengthen the efficacy of AKI. Folic acid (FA) was used as the targeting molecule, and curcumin (Cur) and resveratrol (Res), which are Chinese medicine monomers with anti-inflammatory and antioxidant effects, were used as model drugs. Here, the targeting nanosystem (Cur/Res@FA-F127/TPGS) co-loaded with Cur and Res was successfully synthesized. Finally, the comprehensive therapeutic effect of the nanosystem was evaluated through the targeted and pharmacodynamic researches on the AKI models induced by cisplatin (CDDP) in vitro and in vivo. The studies in vitro proved that the nanosystem could not only specifically target HK-2 cells and promote the effective accumulation of Cur and Res in the kidney, but also effectively improve oxidative stress by eliminating reactive oxygen species (ROS), stabilizing mitochondrial membrane potential (MMP), and reducing the expression of apoptosis-related proteins. The studies in vivo showed that the nanosystem could effectively play the role of anti-oxidation, anti-inflammatory and alleviate fibrosis to reduce the apoptosis and necrosis of renal tubular cells. The nanosystem could coordinately repair damaged HK-2 cells by improving oxidative stress, inhibiting inflammation and tissue fibrosis, which provided a new idea for the treatment of AKI.

Keywords: Acute kidney injury; Fibrosis; Inflammatory factor; NF-κB; Oxidative stress.

MeSH terms

  • Acute Kidney Injury* / chemically induced
  • Acute Kidney Injury* / drug therapy
  • Acute Kidney Injury* / metabolism
  • Apoptosis
  • Cisplatin / pharmacology
  • Curcumin* / pharmacology
  • Curcumin* / therapeutic use
  • Fibrosis
  • Folic Acid / pharmacology
  • Humans
  • Micelles
  • Oxidative Stress
  • Poloxamer / metabolism
  • Poloxamer / pharmacology
  • Poloxamer / therapeutic use
  • Resveratrol / pharmacology

Substances

  • Micelles
  • Poloxamer
  • Folic Acid
  • Curcumin
  • Cisplatin
  • Resveratrol